Open AccessIs adjuvant immunotherapy a new standard for non‐ pathological complete response patients with resectable esophageal squamous cell carcinoma?
Author(s) -
Wang Jun,
Hui Zhouguang,
Pang Qingsong
Publication year - 2022
Publication title -
thoracic cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.823
H-Index - 28
eISSN - 1759-7714
pISSN - 1759-7706
DOI - 10.1111/1759-7714.14641
Subject(s) - medicine , nivolumab , hazard ratio , durvalumab , adjuvant , oncology , adenocarcinoma , esophageal cancer , chemoradiotherapy , gastroenterology , surgery , cancer , immunotherapy , confidence interval